
For much of the past decade, Indian healthtech startups sold convenience, from online doctor consultations and medicine deliveries to app-based diagnostic bookings. The pandemic accelerated adoption and drew venture capital into the sector.
But investor appetite now has become more selective.
Tracxn data showed that Indian healthtech companies raised $626 million across 114 equity rounds in the first nine months of 2026, up from $511 million across 158 rounds in the same period last year, implying more capital was flowing into fewer deals.
Prashant Tandon, co-founder and CEO of Tata 1mg, sees the next phase taking shape around scale, quality and continuity of care. “With a significant push towards compliance and quality, the outpatient pharmacy and labs ecosystem will get more and more organized into large networks which can leverage scale to deliver authenticity with compliance,” he told ETEntrepreneur.
Building healthcare beyond the app
Tandon traced the sector’s evolution to five enablers: digitisation, greater consumer awareness, new payers such as insurers, corporates and the government, technology-led innovation, and the push towards digital public infrastructure and regulation.
The past five to 10 years had laid the foundations through multi-specialty hospitals, single-specialty care chains and venture-backed e-health companies. These had established “the basic building blocks for the next level of innovation”, he said.
Tandon also saw an opportunity in “wellness-oriented as well as condition management companies” leveraging “the available data and continued connection with patients” to focus on “keeping the patient healthy”.
Other opportunities included new care delivery and health financing models, connected medical devices, advanced diagnostics, nutraceuticals and longevity. The potential, he said, lay in “monetizing the value thus created for the patient and the payors”.
“There are clearly better models and sustainable business models now, given a critical scale has been established,” Tandon said.
Extending those models beyond metros remained difficult. Tandon identified three constraints in tier II and tier III markets. These included higher delivery costs combined with lower purchasing power and fewer orders; the difficulty of finding trained workers; and compliance requirements that could make services unviable regardless of location.
“It costs a lot more to deliver a medicine or collect a lab sample from a Tier 2/3 town than it is for a metro,” he said. It was also “extremely hard and more expensive to find trained manpower for various health services”. Licensing and personnel requirements, meanwhile, could remain unchanged across locations.
Despite these constraints, Tandon saw demand growing in smaller markets. Consumers were “seeking much better healthcare”, he said, creating an opportunity for companies to develop new operating models with the government. This would require a positive and nimble approach from all stakeholders, he added.
CureBay offered one example of how companies were addressing the gap. It combines physical centres, digital consultations and on-ground teams to bring consultations, diagnostics, medicines and specialist access closer to rural communities.
Its founder and CEO, Priyadarshi Mohapatra, challenged the assumption that rural households were unwilling to pay for healthcare. Families already spent on travel to distant towns, lost wages, repeat visits and delayed treatment. “The willingness to pay is there. What has been missing is quality care close to home, delivered by people they can rely on,” he said.
CureBay measured sustainability through its relationship with families over time, using follow-ups, preventive screenings and programmes such as CureBay Kavach. Local employees, known as Swasthya Mitras, helped families navigate diagnosis, treatment and recovery. “Technology helps us scale, but trust is what sustains the business,” Mohapatra said.
Expansion depended on attracting and retaining clinicians, building reliable diagnostic and medicine supply chains, and addressing the limited coverage of outpatient and preventive care, most of which remained out-of-pocket.
Mohapatra argued that public-private collaboration could help private networks complement government infrastructure in early detection, follow-up and preventive care.
Where the state steps in
The Department of Pharmaceuticals’ ₹5,000 crore under the promotion of research and innovation in pharma-medtech (PRIP) scheme announced a discovery track in September, offering startups and MSMEs up to ₹50 crore for developing new chemical and biological entities, subject to at least 25 per cent institutional funding. Its first call approved 41 projects worth around ₹1,600 crore, with another ₹3,020 crore in private investment expected.
Separately, the Technology Development Board opened applications in October for its medical technology and therapeutics programme, offering loans at 5 per cent interest or equity participation. It also signed an agreement to provide Peptris Technologies ₹86 crore in optionally convertible debt under the RDI Fund to advance four AI-discovered drug candidates towards clinical trials.
Chetan Mehta, founding partner of AUM Ventures, said such projects underlined the need for patient capital, including specialist venture funds, government grants and strategic investors familiar with healthcare’s development cycles. India also needed better access to clinical trials and testing facilities, alongside more predictable regulatory approval pathways, he believes.
Towards the end of September, the National Health Authority also announced a Secure Data Environment under the Ayushman Bharat Digital Mission, developed with the Indian Institute of Science, Bengaluru. It is intended to let approved entities analyse de-identified health data in a controlled environment, supporting research and data-led healthcare products, including AI applications.
Mohapatra believes the next challenge is ensuring rural primary care is “not just available but consistent and of reliable quality”.
What investors want now
Mehta said the first wave of healthcare startups had focused on access through telemedicine, online pharmacies, marketplaces and digital health platforms. Investor expectations had since shifted towards differentiated technology, clinical validation, defensible business models and sustainable unit economics.
“Some of the most interesting opportunities are emerging in AI-led diagnostics and clinical decision support, advanced medical devices, precision diagnostics, biotechnology, genomics and technology-enabled specialised healthcare,” he added.
These opportunities extend beyond digital health into AI-led drug discovery, novel therapeutics, surgical robotics and advanced medical devices. Such businesses typically require longer development cycles, substantial capital and clinical validation before reaching commercial scale.
Mehta said his assessment of a startup centred on the significance of the clinical problem, the strength of its technology and intellectual property, its regulatory and clinical validation pathway, the identity and willingness of the paying customer, and the prospects for sustainable unit economics.
Long development cycles did not necessarily make a business less viable. A company spending five years developing a medical device could be as attractive as a software business generating revenue in its first year, he said. Investment, however, had to be tied to milestones, from prototype development and clinical validation to regulatory approval and commercial adoption.
Mehta did not see digital health and deeptech as competing opportunities. “Digital health can improve access and efficiency, while medtech and biotech create deeper technology differentiation and intellectual property. India needs both,” he said.
Recent funding rounds reflected the breadth of this shift, spanning hospital-led care, rural healthcare delivery, AI-assisted screening and medical tourism.
Managed healthcare and subscription-based health services company Even Healthcare raised $50 million in a series B led by Khosla Ventures to open five hospitals. CureBay secured around ₹100 crore in a pre-series C round, comprising equity led by IvyCap Ventures and debt from Trifecta Capital, Alteria Capital and VentureSoul Partners. Jaipur-based Aignosis raised ₹4 crore in a seed round backed by Antler, Nikhil Kamath and angel investors to scale its AI-assisted autism screening tools.
The challenge now is to build healthcare businesses that can deliver quality care at scale without losing sight of affordability. As Tandon put it, the goal is to combine “authenticity, affordability and convenience”.